Form 4: Arcus Biosciences Director Acquires 5,000 Stock Options

Director David L. Lacey acquired 5,000 stock options in Arcus Biosciences, Inc. on January 23, 2025.

Summary

• On January 23, 2025, David L. Lacey, a director of Arcus Biosciences, Inc., acquired 5,000 stock options.
• The exercise price of these options is $13.33.
• The options become exercisable in 24 equal monthly installments starting after January 1, 2025, contingent upon continued service to the company.
• Following the transaction, Mr. Lacey directly owns 57,652 shares of common stock and 5,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance, but rather a routine part of executive compensation.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment, as it can be interpreted as a sign of confidence in the company's future.

Key Dates